|
시장보고서
상품코드
2054274
항비만제 시장 : 작용기전별, 처방약 및 일반용 의약품별 및 지역별Anti-Obesity Drug Market, By Mechanism of Action, By Prescription/Non- prescription, And by Region |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항비만제 시장은 2026년에 305억 8,000만 달러로 추계되고 있으며, 2033년까지 986억 3,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 18.2%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모 : 2026년 | 305억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR : 2026-2033년 | 18.20% | 시장 규모 예측 : 2033년 | 986억 3,000만 달러 |
비만이란 일반적으로 체지방이 과다한 상태를 말합니다. 성인의 비만에 대한 일반적인 기준으로 체질량 지수(BMI)가 30 이상인 경우를 꼽습니다. 항비만제는 체내 콜레스테롤 수치를 낮춤으로써 체중을 감량하기 위해 사용되는 의약품입니다. 이러한 약물은 식욕과 칼로리 섭취를 조절함으로써 인체의 기본 기능에 영향을 미칩니다. 항비만제는 일반적으로 비만 치료에 사용됩니다. 미국 식품의약국(FDA)과 유럽의약품청(EMA)은 비만 치료를 위해 여러 가지 항비만제를 승인했습니다.
시장 역학
비만 인구 증가 및 관련 만성 질환 증가, 과체중과 비만에 대한 우려 고조, 항비만제 수요 증가, 연구 개발 활성화, 그리고 코로나19 팬데믹은 예측 기간 동안 세계 항비만제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 예를 들어, 2022년 6월, 미국 FDA는 비만 및 과체중이며, 적어도 하나의 체중 관련 질환(고혈압, 고콜레스테롤, 2형 당뇨병 등)을 가진 성인의 만성적인 체중 관리를 위해, 저칼로리 식이요법 및 운동량 증가와 병용하여 사용하도록 세마글루타이드 2.4mg을 승인했습니다.
또한, 2022년 1월, 세계 헬스케어 기업인 노바티스는 ‘비마그마브’라는 임상시험용 약물의 2상 임상시험 결과를 발표했습니다. 이 약제는 비만 치료에 있어 유효성이 있을 가능성이 있습니다. 현재 이 약물은 노바티스의 파이프라인에서 연구가 진행 중입니다.
본 조사의 주요 특징
- 본 조사는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 세계 항비만제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업의 주요 정보, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 본 보고서의 인사이트를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 항비만제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업 및 금융 애널리스트를 포함한 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 항비만제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 항비만제 시장 : 약제 유형별(2021-2033년)
제5장 세계의 항비만제 시장 : 약제 클래스별(2021-2033년)
제6장 세계의 항비만제 시장 : 투여 경로별(2021-2033년)
제7장 세계의 항비만제 시장 : 유형별(2021-2033년)
제8장 세계의 항비만제 시장 : 성별(2021-2033년)
제9장 세계의 항비만제 시장 : 연령층별(2021-2033년)
제10장 세계의 항비만제 시장 : 유통 채널별(2021-2033년)
제11장 세계의 항비만제 시장 : 지역별(2021-2033년)
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
AJY 26.06.17Anti-Obesity Drug Market is estimated to be valued at USD 30.58 Bn in 2026 and is expected to reach USD 98.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 18.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 30.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 18.20% | 2033 Value Projection: | USD 98.63 Bn |
Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.
Market Dynamics
Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2022, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.
Moreover, in January 2022, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Anti-Obesity Drug Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Anti-Obesity Drug Market
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Prescription Drugs
- Over-the-Counter (OTC) Drugs
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- GLP-1 Receptor Agonists
- Semaglutide
- Liraglutide
- Tirzepatide
- MC4R (Melanocortin-4 Receptor) Agonists
- Setmelanotide
- Lipase Inhibitors
- Orlistat
- Noradrenergic & Serotonergic Drugs
- Phentermine
- Diethylpropion
- Phendimetrazine
- Combination Therapies
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Others
- Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
- Empagliflozin
- Canagliflozin
- Bile Acid Sequestrants
- Colesevelam
- Amylin Analogs
- Pramlintide
- Others (Late Phase Drugs, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Others (Transdermal)
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Brand
- Generic
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Geriatric
- Pediatric
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk
- GlaxoSmithKline
- AstraZeneca
- Pfizer
- Merck & Co.
- Sanofi
- Amgen
- Eli Lilly and Company
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Abbott Laboratories
- Orexigen Therapeutics
- Zafgen
- Rhythm Pharmaceuticals
- Currax Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Anti-Obesity Drug Market, By Drug Type
- Global Anti-Obesity Drug Market, By Drug Class
- Global Anti-Obesity Drug Market, By Route of Administration
- Global Anti-Obesity Drug Market, By Type
- Global Anti-Obesity Drug Market, By Gender
- Global Anti-Obesity Drug Market, By Age Group
- Global Anti-Obesity Drug Market, By Distribution Channel
- Global Anti-Obesity Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Anti-Obesity Drug Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Prescription Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Over-the-Counter (OTC) Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Anti-Obesity Drug Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- GLP-1 Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Semaglutide
- Liraglutide
- Tirzepatide
- Semaglutide
- MC4R (Melanocortin-4 Receptor) Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Setmelanotide
- Lipase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Orlistat
- Noradrenergic & Serotonergic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phentermine
- Diethylpropion
- Phendimetrazine
- Phentermine
- Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Others
- Phentermine/Topiramate
- Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Empagliflozin
- Canagliflozin
- Empagliflozin
- Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Colesevelam
- Amylin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pramlintide
- Others (Late Phase Drugs, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Anti-Obesity Drug Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Transdermal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Anti-Obesity Drug Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Anti-Obesity Drug Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Anti-Obesity Drug Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Anti-Obesity Drug Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Anti-Obesity Drug Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orexigen Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zafgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rhythm Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Currax Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
